BATON ROUGE, LA--(Marketwired - February 02, 2017) - OncBioMune Pharmaceuticals, Inc. (OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to announce that the Company's abstract illustrating research on its novel therapeutic cancer vaccine, has been accepted for a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2017 in Washington, D.C.
The technology being presented at AACR serves as the foundation for ProscaVax, the Company's novel therapeutic cancer vaccine currently in a Phase 1 clinical trial funded in part by the Department of Defense, with a Phase 2 trial planned at a prominent cancer research university in the Northeast U.S. and a Phase 2/3 nearing enrollment in Mexico through a Joint Venture with the Company's acquisition target Vitel Laboratorios S.A. de C.V.
Dr. Jonathan Head, Chief Executive Officer at OncBioMune, will be presenting the abstract titled, "Inhibition of 4T1 mammary tumor growth in BALB/c mice by subcutaneous and intraperitoneal injection of a 4T1 whole cell vaccine containing IL-2 and GM-CSF as adjuvants" as part of the Immunology Session at AACR on Monday, April 3, 2017 from 8:00 AM - 12:00 PM ET at the Walter E. Washington Convention Center, Halls A-C, Poster Section 28.
"We are delighted to once again be attending one of the world's leading oncology meetings to present information on ProscaVax and network with peers," commented Dr. Jonathan Head. "Our poster this year provides compelling evidence about the therapeutic benefit of our vaccine technology in slowing tumor growth in a mouse model of breast cancer and demonstrates the scalability of our platform to address different cancer lines."
Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/.
About OncBioMune Pharmaceuticals, Inc.
OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary Vaccine Technology that is designed to stimulate the immune system to attack its own cancer while not hurting the patient. Our lead product, ProscaVax™ is scheduled to commence a Phase 2 clinical study in 2016. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.
This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor there be any sale of these securities in any jurisdiction in which such offer solicitation or sale are unlawful prior to registration or qualification under securities laws of any such jurisdiction.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause OncBioMune Pharmaceuticals' actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. OncBioMune Pharmaceuticals has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are OncBioMune Pharmaceuticals' need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that OncBioMune Pharmaceutical's vaccines and therapeutics may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in OncBioMune Pharmaceutical's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. OncBioMune Pharmaceuticals undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.